Abstract

A method for producing a homocoupling reaction product of an organic halogen compound includes subjecting the organic halogen compound to a reaction in the presence of a nickel catalyst under a condition (a) and/or a condition (b) by a mechanochemical method: (a) a condition where the amount of a solvent used is 0.8 mL or less relative to 1 mmol of the organic halogen compound; (b) a condition where a heteroatom-containing compound is present. The organic halogen compound is represented by formula A1-Xm wherein A1 represents an optionally substituted m-valent aromatic hydrocarbon group, m-valent aromatic heterocyclic group, m-valent heterocyclic group, m-valent aliphatic hydrocarbon group, or m-valent unsaturated aliphatic hydrocarbon group; each X independently represents chlorine, bromine, or iodine; and m represents an integer of 1 or more.

IPC Classes  ?

• C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07C 5/00 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
• C07C 41/01 - Preparation of ethers
• C07C 45/00 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds
• C07C 67/00 - Preparation of carboxylic acid esters
• C07C 209/00 - Preparation of compounds containing amino groups bound to a carbon skeleton
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07F 5/04 - Esters of boric acids

Abstract

Provided is a catalyst metal particle containing Rh as a main component that can improve catalytic activity and a catalyst containing the catalyst metal particle. The catalyst metal particle according to the present disclosures includes a composition in terms of atomic ratio represented by the formula RhxIryPtz, wherein x+y+z=100, 40≤x≤80, 10≤y≤40, and 10≤z≤40.

IPC Classes  ?

• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• F01N 3/28 - Construction of catalytic reactors

Abstract

The purpose of the present invention is to provide: a plant having an increased yield of storage tissue; and a method for producing the plant. It was discovered that the yield of storage tissue in a plant can be increased by expressing, in the storage tissue of the plant, a sucrose synthase having a substrate specificity to adenosine diphosphate.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12N 9/10 - Transferases (2.)
• C12N 15/54 - Transferases (2)

Abstract

This manufacturing method is for manufacturing an observation device (110) for observing precipitation particles such as raindrops. The manufacturing method comprises: a step for preparing an antenna module (30) that transmits electromagnetic waves (E) and receives electromagnetic waves (E) reflected by a storage container (20) and electromagnetic waves (E) reflected by precipitation particles; a step for outputting information relating to a placement position for placing the antenna module (30) in the storage container (20) on the basis of the value of the dielectric constant of the wall (21) of the storage container (20), the value of the thickness of the wall (21), and a theoretical formula for converting a function indicating the relationship between the electromagnetic waves (E) transmitted from the antenna module (30) and the electromagnetic waves (E) reflected by the storage container (20) into a function having, as variables, the dielectric constant of the wall (21), the thickness of the wall (21), and the placement position; and a step for storing the antenna module (30) in the storage container (20) and placing the antenna module (30) at the placement position.

IPC Classes  ?

• G01W 1/14 - Rainfall or precipitation gauges

Abstract

[OBJECT] To improve workability. [SOLUTION] A method for producing a self-hardening material, includes: a first step of subjecting fly ash to unburned carbon removal treatment to produce unburned carbon removal-treated fly ash; a second step of subjecting the unburned carbon removal-treated fly ash to mechanochemical treatment to activate a surface of the unburned carbon removal-treated fly ash; a third step of mixing a strong alkaline solution and silicon fine powder to prepare a silicon mixture in which a silicon component is dissolved in the strong alkaline solution; and a fourth step of mixing the unburned carbon removal-treated fly ash whose surface has been activated and the silicon mixture.

IPC Classes  ?

• B09B 3/25 - Agglomeration, binding or encapsulation of solid waste using mineral binders or matrix
• C04B 18/08 - Flue dust
• C04B 28/26 - Silicates of the alkali metals

Abstract

The present invention provides a pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a nucleic acid that suppresses the expression of Chromosome 11 Open Reading Frame 97 (C11orf97). With the present invention, it becomes possible to treat cancer.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided is a composition or the like useful for filling an intracerebral hematoma cavity in a subject. This composition for filling an intracerebral hematoma cavity contains an alginic acid monovalent metal salt, and is used in combination with mesenchymal stem cells.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 27/38 - Animal cells
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

The present invention is a post-chemotherapy prognosis prediction method for a canine with lymphoma, including: a measurement step of measuring a methylation rate of one or more CpG sites selected from the group consisting of Chr4: 29559893 and Chr1: 14232692, in DNA recovered from a biological sample collected from a canine as a prediction target; and a prediction step of predicting a post-chemotherapy prognosis for a canine with lymphoma, based on the methylation rate measured in the measurement step and a preset reference value, in which the reference value is a value for differentiating between a canine having a favorable post-chemotherapy prognosis and a canine having a poor post-chemotherapy prognosis, which is set for each methylation rate of each CpG site.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Skeleton information is visualized in response to diverse needs of individual sites. A gait behavior visualization system stores skeleton data, which is time-series data indicating trajectories of a plurality of sites set for a measurement subject in a three-dimensional space for a gait of the measurement subject, period determination data, which is information used for specifying a time corresponding to each of periods of one gait for the skeleton data, and a perspective defined by designating the period, the site, and a displaying method for the trajectory; specifies a time corresponding to the period for the skeleton data by comparing the skeleton data and the period determination data; and generates, based on the skeleton data for the period designated in the perspective, a screen on which the trajectory of the site designated in the perspective is presented according to the displaying method designated in the perspective.

IPC Classes  ?

• G06T 7/215 - Motion-based segmentation

Abstract

The present invention provides an aggregation inhibitor that inhibits aggregation of TDP-43 or a partial protein thereof, the aggregation inhibitor containing, as an active ingredient, an RNA molecule having either a G4C2 sequence, which is a base sequence represented by GGGGCC, or an A4U2 sequence, which is a base sequence represented by AAAAUU; and also provides the aggregation inhibitor wherein the RNA molecule includes RNA in which from one to eight of the G4C2 sequences are linked; and a pharmaceutical composition containing one of the aggregation inhibitors as an active ingredient, wherein the pharmaceutical composition is administered to inhibit the aggregation of TDP-43 or a partial protein thereof.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention pertains to a vascular endothelial cell protecting agent, a blood-cerebrospinal fluid barrier protecting agent, and a central nervous system protecting agent, comprising at least one compound selected from the group consisting of mubritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof. Additionally, the present invention pertains to a pharmaceutical composition for preventing and/or treating diseases associated with blood-cerebrospinal fluid barrier impairments, such as damage to the central nervous system, infarction and hemorrhaging, inflammatory diseases of the central nervous system, degenerative diseases of the central nervous system, symptomatic nerve diseases, spinal cord impairments associated with spinal cord degeneration, drug-based impairments, infectious diseases, or anaphylaxis. The pharmaceutical composition comprises at least one compound selected from the group consisting of mubritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof.

IPC Classes  ?

• A61K 31/29 - Antimony or bismuth compounds
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61P 39/00 - General protective or antinoxious agents

Abstract

The purpose of the present disclosure is to provide a novel component that is useful as an active ingredient in an autophagy inducer. A vegetable ceramide according to the present disclosure is useful as an active ingredient in an autophagy inducer.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/68 - Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
• A61K 8/9783 - Angiosperms [Magnoliophyta]
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin

Abstract

This warehouse system (100) comprises: an automated warehouse (1) that includes a plurality of transport devices (51-53), each processing a task for transporting a package from a plurality of storage spaces (46) to a plurality of shipping ports (441-445); and a task management device (2) that manages a normal task by using a plurality of queues respectively corresponding to the plurality of shipping ports (441-445). When an interrupt task arises, the task management device (2) adds the interrupt task to a queue corresponding to a designated shipping port among the plurality of shipping ports (441-445), and calculates, for each P, the number of completed tasks, which is the number of tasks that can be processed within a prescribed time by all the plurality of transport devices, on the assumption that a transport device , which is P-th (P≧2) in the order of becoming available, processes the interrupt task. The task management device (2) identifies P that satisfies the condition determined with regard to the number of completed tasks, and allocates the interrupt task to the identified P-th transport device.

IPC Classes  ?

• B65G 1/00 - Storing articles, individually or in orderly arrangement, in warehouses or magazines
• B65G 1/137 - Storage devices mechanical with arrangements or automatic control means for selecting which articles are to be removed
• G06Q 10/08 - Logistics, e.g. warehousing, loading or distributionInventory or stock management

Abstract

In the present invention, the accuracy of prediction of the therapeutic effect of the immune checkpoint inhibitor is sufficiently high.　Test data and training data for model training are prepared using the effect of administering an immune checkpoint inhibitor to a patient group and the results of RNA sequence analysis pertaining to the patient group (S11). A combination of a plurality of genes including the NLRC5 gene is selected (S12), and a model is trained using training data relating to the combination of genes (S13). The trained model is tested using the test data (S14). After training all combinations of genes (S15, Yes), a test result is output (S16). A biomarker comprising a combination of genes having high accuracy of prediction of therapeutic effect is determined (S17).

IPC Classes  ?

• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention accurately generates right and left optical vortices. This optical vortex generation device (10) comprises: a modulation unit (12) that generates, from incident light, first modulated light having a spin angular momentum; and a first spin-orbit converter (13) that generates, from the first modulated light, second modulated light having an orbital angular momentum.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
• G01N 21/19 - Dichroism
• G02B 5/30 - Polarising elements
• G02B 21/06 - Means for illuminating specimen
• G02B 27/28 - Optical systems or apparatus not provided for by any of the groups , for polarising

Abstract

Provided is a prophylactic and/or therapeutic agent for photodermatitis caused by light exposure. This prophylactic and/or therapeutic agent for a skin disorder caused by light exposure contains an inhibitor for cellular senescence-associated secretory phenotype factors (SASP factors) as an active ingredient. As a result of exploring responses to light exposure in melanocytes and comprehensively analyzing molecules that can be therapeutic target seeds related to the skin disorder, it was shown that cellular senescence occurs in melanocytes after light exposure. In melanocytes having undergone cellular senescence, enhanced expression of an SASP factor group was observed, and this led to the finding that an inhibitor for SASP factors is effective for preventing and/or treating the skin disorder.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/121 - Ketones acyclic
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/6851 - Quantitative amplification

Abstract

The present disclosure addresses the problem of providing a dosage regimen for an orally administered pharmaceutical composition that is for treating and/or preventing autosomal dominant polycystic kidney disease and that contains, as an active ingredient, tamibarotene. The present disclosure provides a pharmaceutical composition that is for treating or preventing autosomal dominant polycystic kidney disease, that contains tamibarotene, and that is to be orally administered to an autosomal dominant polycystic kidney disease patient in an amount of 1.4-5.5 mg/day, particularly about 4 mg/day, in terms of the tamibarotene.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

[Problem] The purpose of the present invention is to provide, as each useful agent that contains DHMBA as an active ingredient, a cytoprotective agent against ferroptosis, the cytoprotective agent containing DHMBA as an active ingredient and having a cytoprotective action against ferroptosis by verifying the effect of suppressing ferroptosis cell death of DHMBA using a DN model mouse and a human renal tubular cell HK-2. [Solution] The present invention provides a cell agent against ferroptosis, the cell agent containing 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient and having a cytoprotective action against ferroptosis.

IPC Classes  ?

• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 39/00 - General protective or antinoxious agents

Abstract

Provided are: at least one imaging device disposed on an inner surface side of a non-pressurization panel which is attached to a non-pressurized region of a body of a pressurized aircraft; an analysis-image generation system including the imaging device; and a non-pressurization panel that is attached to a non-pressurized region of a body of an aircraft.

IPC Classes  ?

• G03B 17/56 - Accessories
• B64C 1/14 - WindowsDoorsHatch covers or access panelsSurrounding frame structuresCanopiesWindscreens
• B64C 11/00 - Propellers, e.g. of ducted typeFeatures common to propellers and rotors for rotorcraft
• B64D 47/08 - Arrangements of cameras
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G03B 30/00 - Camera modules comprising integrated lens units and imaging units, specially adapted for being embedded in other devices, e.g. mobile phones or vehicles
• H04N 23/57 - Mechanical or electrical details of cameras or camera modules specially adapted for being embedded in other devices

Abstract

The objective of the present invention is to provide an annular device that can suppress the effect of frictional forces generated between the annular device and the eyelid conjunctiva during blinking and that can exhibit excellent stability on the eye when worn, as compared to the previous annular devices. The objective can be achieved by an annular device configured to be worn over a surface of a sclera, comprising: an opening configured to expose a cornea; and a body portion having a slab-off region and a non-slab-off region, wherein the slab-off region is formed such that a maximum thickness thereof gradually decreases from a right end side toward upper and lower end sides and from a left end side toward upper and lower end sides; and the like.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery

Abstract

A new dosage regimen of a pharmaceutical composition comprising tamibarotene as the active ingredient for treating autosomal dominant polycystic kidney disease. A pharmaceutical composition comprising tamibarotene for the treatment or prevention of autosomal dominant polycystic kidney disease (ADPKD), wherein the composition is administered orally to a patient with ADPKD in an amount of 1.4-5.5 mg/day, particularly 4.0 mg/day of tamibarotene.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula (I): The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula (I): wherein Y is N or the like; R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is substituted or unsubstituted aromatic carbocyclyl or the like; R3 is substituted or unsubstituted aromatic heterocyclyl or the like; —X— is —NH— or the like; m is 1 or the like; R5a is each independently a hydrogen atom or the like; R5b is each independently a hydrogen atom or the like; n is 1 or the like; R4a is each independently a hydrogen atom or the like; and R4b is each independently a hydrogen atom or the like, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 31/14 - Antivirals for RNA viruses
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems

Abstract

The present invention provides peptides that comprise an amino acid sequence that has 5–20 residues and includes an amino acid sequence that is represented by Xaa1-Xaa2-L-F-F (in which Xaa1 and Xaa2 are each independently any amino acid residue), the peptides having the ability to inhibit T cell activation, peptides obtained by adding a membrane-permeable peptide to a terminus of the abovementioned peptides via a linker sequence or not, nucleic acids that code for the peptides, and pharmaceutical compositions that include the peptides or the nucleic acids.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 37/08 - Antiallergic agents
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention simultaneously achieves, in allogeneic hematopoietic cell transplantation as a treatment for blood cancer, enhancement of a graft-versus-tumor effect (GVT effect) and/or a graft-versus-leucocyte effect (GVL effect) and suppression of graft-versus-host disease (GVHD).　The present invention relates to a pharmaceutical composition which is for enhancement of a GVL and/or GVT effect in a hematopoietic cell transplantation treatment and which comprises ropeginterferon.

IPC Classes  ?

• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 38/21 - Interferons
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present disclosure provides a tire rubber composition and a tire which are capable of changing tire performance in response to temperature changes. The present disclosure relates to a tire rubber composition containing: a rubber component including at least one selected from the group consisting of polyisoprene rubber, polybutadiene rubber, and styrene-butadiene rubber; a cross-linking agent; carbon black; a plasticizer; and a temperature-responsive material A containing a carboxyl group-containing polymer and a metal salt, the tire rubber composition containing, per 100 parts by mass of the rubber component, the cross-linking agent in an amount of more than 0 parts by mass and less than 10 parts by mass, the carbon black in an amount of more than 0 parts by mass and less than 100 parts by mass, and the plasticizer in an amount of more than 5 parts by mass.

IPC Classes  ?

• B60C 1/00 - Tyres characterised by the chemical composition or the physical arrangement or mixture of the composition
• C08K 3/04 - Carbon
• C08K 3/36 - Silica
• C08K 5/20 - Carboxylic acid amides
• C08L 9/00 - Compositions of homopolymers or copolymers of conjugated diene hydrocarbons

Abstract

A continuous flow microfluidic system for continuous flow operation of a microfluidic chip, in which a pulsation rate of a continuous flow formed by the system is 5% or less. Even when a fluid sample is fed into a microfluidic chip at a high pressure, it is possible to satisfactorily and stably produce self-assembled substance particles such as lipid nanoparticles having high size uniformity, and it is possible to mass-produce such self-assembled substance particles.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Provided are a pressure sensor and the like that are capable of accurately detecting, as a surface, a pressure applied to an object from the outside. The present invention is provided with: a plurality of sensor pixels PX that are arranged in a surface formation, the sensor pixels PX being each equipped with a membranous pressure-sensitive film 2 having a resistance value that varies by the front surface of the pressure-sensitive film 2 being pressed, and a first electrode layer 4 and a second electrode layer 6 laminated only on the back surface of the pressure-sensitive film 2; and a drive circuit that drives each of the sensor pixels PX, the drive circuit detecting, according to variations in the resistance values caused by pressing the plurality of sensor pixels PX, the pressure of the pressing for each of the sensor pixels PX.

IPC Classes  ?

• G01L 5/00 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes

Abstract

A latent heat storage body microcapsule includes a core including gallium or gallium alloy; and a shell covering the core and including gallium oxide. A method for producing the same includes a particle-forming step of forming gallium or an alloy of gallium in a liquid state into particles; a water treatment step of heating the particles in distilled water to form a gallium hydrate on a surface of each of the particles; and an oxidation treatment step of oxidizing the gallium hydrate to form a shell including gallium oxide. The method includes a particle-forming step of forming gallium or an alloy of gallium in a liquid state into particles; a cooling step of cooling the particles to a solid state; and a pH treatment step of immersing the particles in an aqueous solution having a predetermined pH to form a shell including gallium hydrate.

IPC Classes  ?

• C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
• B22F 1/145 - Chemical treatment, e.g. passivation or decarburisation
• B22F 1/16 - Metallic particles coated with a non-metal

Abstract

The present disclosure provides a sulfide solid electrolyte sheet having sufficient self-supporting properties and uniformity. Provided is a method for manufacturing a sulfide solid electrolyte sheet, the method comprising: preparing a slurry by mixing a sulfide solid electrolyte, a non-polar solvent, and at least one polar solvent selected from ethers and alcohols; impregnating a support having voids with the slurry; and removing the non-polar solvent and the polar solvent from the support after impregnation with the slurry.

IPC Classes  ?

• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01B 1/10 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances sulfides
• H01M 10/0562 - Solid materials

Abstract

An image diagnostic device (100) comprises: a bony acetabular line detection unit (153) that detects, on the basis of a pixel value of each pixel of an ultrasonic image acquired by an acquisition unit (152), a bony acetabular line in the ultrasonic image; and a baseline detection unit (154) that detects, on the basis of the pixel value of each pixel of the ultrasonic image acquired by the acquisition unit (152), a straight line indicating an iliac outer wall in the ultrasonic image and detects a baseline parallel to the detected straight line indicating the iliac outer wall and passing through a bony acetabulum or a lower end of the iliac outer wall at an end portion of the bony acetabular line detected by the bony acetabular line detection unit (153).

IPC Classes  ?

• A61B 8/14 - Echo-tomography

Abstract

A continuous flow microfluidic system for continuous flow operation of a microfluidic chip, in which a pulsation rate of a continuous flow formed by the system is 5% or less. A continuous flow microfluidic system for continuous flow operation of a microfluidic chip, in which a pulsation rate of a continuous flow formed by the system is 5% or less. Even when a fluid sample is fed into a microfluidic chip at a high pressure, it is possible to satisfactorily and stably produce self-assembled substance particles such as lipid nanoparticles having high size uniformity, and it is possible to mass-produce such self-assembled substance particles.

IPC Classes  ?

• B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
• B01F 23/40 - Mixing liquids with liquidsEmulsifying
• B01F 23/45 - Mixing liquids with liquidsEmulsifying using flow mixing
• B01F 25/421 - Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions by moving the components in a convoluted or labyrinthine path
• B01F 35/71 - Feed mechanisms
• B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions

Abstract

The present invention addresses the problem of suppressing production of methane by ruminants. Provided is a composition for reducing production of methane in the rumen of a ruminant, the composition comprising a Pongamia pinnata seed oil. Also provided is a ruminant feed composition comprising 0.1-10% of a Pongamia pinnata seed oil. The Pongamia pinnata seed oil may be contained as refined oil, crude oil, or a degummed deacidified product of crude oil of Pongamia pinnata seeds.

IPC Classes  ?

• A23K 10/37 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms from waste material
• A23K 50/10 - Feeding-stuffs specially adapted for particular animals for ruminants

Abstract

x1-x3x1-x33, and a protective layer comprising amorphous oxide. The dielectric layer is deformed by inverse piezoelectric effect by irradiation light.

IPC Classes  ?

• H10N 30/20 - Piezoelectric or electrostrictive devices with electrical input and mechanical output, e.g. functioning as actuators or vibrators
• H10N 30/853 - Ceramic compositions

Abstract

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 37/04 - Immunostimulants

Abstract

According to the present invention, the internal temperature of edible animals is appropriately determined.　A freshness evaluation system 1 has a test kit 100 and a server 200 that can communicate with each other via a network N. The test kit 100 has a detector body 11 and a test body 20. The detector body 11 transmits results of temperature detection inside the test body 20 to the server 200. The server 200 holds information about a function representing the relationship between the temperature inside the test body 20 and the temperature inside the meat of the edible animal. The server 200 estimates the temperature inside the meat of the edible animal on the basis of the information and the results of temperature detection inside the test body 20. The server 200 calculates an evaluation value representing the freshness of the meat of the edible animal on the basis of the estimated temperature.

IPC Classes  ?

• G01N 33/12 - MeatFish

Abstract

PROBLEM TO BE SOLVED: The purpose of the present invention is to provide a compound capable of safely and efficiently introducing into cells an antibody drug capable of inhibiting proliferation of cancer cells. SOLUTION: According to the present invention, the proliferation of cancer cells is suppressed by introducing an antibody that binds specifically to IL-6 or a receptor thereof into cells using the PIECE method and specifically suppressing the autocrine intracellular IL-6 signaling pathway. This configuration makes it possible to target a pathogenic signaling pathway localized in a cell, and to provide a novel and practical technique for intracellular delivery of antibody drugs and cancer treatment methods that overcomes the application limits of conventional antibody drugs.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition comprising a retinoic acid receptor (RAR) agonist.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/203 - Retinoic acids
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing the neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). [In formula (I), R1 is a C1-22 hydrocarbon group; three R1 groups in one molecule may be the same as or different from each other; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R2 and R3 are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.] The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing the neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). [In formula (I), R1 is a C1-22 hydrocarbon group; three R1 groups in one molecule may be the same as or different from each other; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R2 and R3 are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.]

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms

Abstract

Disclosed herein include methods, compositions, and kits suitable for use in enhancing adoptive T cell therapy. In some embodiments, the method comprises contacting isolated organelle complexes with a population of T cells to generate a population of T cells comprising the organelle complexes. The organelle complexes can comprise mitochondria and one or more of endoplasmic reticulum, peroxisomes, lysosomes, and Golgi apparatus. The population of T cells can exhibit one or more of enhanced expansion capability, enhanced cytotoxicity against target cells, enhanced resistance to exhaustion, and enhanced persistence, as compared to a population of T cells that do not comprise exogenous organelle complexes

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

[Problem] The present invention has been made in response to the need to elucidate the mechanism of action underlying a previously confirmed reduction in plasma and liver total cholesterol levels. The present invention relates to producing and providing an inhibitor that contains 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient and is highly effective for directly suppressing and inhibiting a cholesterol synthesis pathway by acting on HMGCR via SREBP2. [Solution] The present invention is characterized by having suppressive and inhibitory effects on a cholesterol synthesis pathway on the basis of the action of 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient on HMGCR via SREBP2.

IPC Classes  ?

• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61P 3/06 - Antihyperlipidemics

Abstract

The present invention provides a method for economically producing an α-methylene aldehyde compound via a condensation reaction between a formaldehyde and an aldehyde compound, while suppressing the use of a liquid acid. Used is a method for producing an α-methylene aldehyde compound, wherein an α-methylene aldehyde compound represented by general formula (2) is produced via a condensation reaction between a formaldehyde and an aldehyde compound represented by general formula (1) in the presence of a metal oxide catalyst and an amine. (In general formula (1), R1 represents a C1-7 aliphatic hydrocarbon group, and in general formula (2), R1 represents a C1-7 aliphatic hydrocarbon group.)

IPC Classes  ?

• C07C 45/75 - Reactions with formaldehyde
• C07B 61/00 - Other general methods
• C07C 47/22 - AcrylaldehydeMethacrylaldehyde

Abstract

Provided is a novel method that makes it possible to economically produce an α-methylene aldehyde compound by condensation of formaldehyde and an aldehyde compound. The present invention is a production method for an α-methylene aldehyde compound that involves condensing formaldehyde and an aldehyde compound represented by general formula (1) in the presence of a metal oxide catalyst to produce an α-methylene aldehyde compound represented by general formula (2). (In general formula (1), R1 represents a C1–7 aliphatic hydrocarbon group.) (In general formula (2), R1 represents a C1–7 aliphatic hydrocarbon group.)

IPC Classes  ?

• C07C 45/75 - Reactions with formaldehyde
• C07B 61/00 - Other general methods
• C07C 47/22 - AcrylaldehydeMethacrylaldehyde

Abstract

The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.

IPC Classes  ?

• A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
• A61K 9/51 - Nanocapsules
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The purpose of the present disclosure is to provide a pharmaceutical composition having excellent therapeutic effects in the treatment of central nervous system diseases.　This pharmaceutical composition for intravascular administration is used for treating central nervous system diseases and contains a purified extracellular vesicle product. The purified extracellular vesicle product is obtained by a method for producing a purified extracellular vesicle product, the method comprising: (i) a purification step for bringing a solution to be treated containing extracellular vesicles and foreign substances into contact with size-exclusion and anion-exchange carriers to obtain a treated solution containing the extracellular vesicles; and (ii) a membrane filtration step for subjecting the treated solution to membrane filtration to obtain a concentrated solution of the extracellular vesicles. The pharmaceutical composition has excellent therapeutic effects in the treatment of central nervous system diseases.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided is a fluorescence microscope in which an irradiation optical system, a light focusing optical system, and a sample conveyance unit hardly interfere with each other and a degree of freedom in design is high. A fluorescence microscope (1) includes: an irradiation optical system (10) that irradiates a sample (S) with an excitation light beam to cut the sample; a light focusing optical system (20) having an optical axis perpendicular to an optical axis of the irradiation optical system (10); and a sample conveyance unit that conveys the sample (S) in a direction intersecting with a plane formed by the optical axis of the irradiation optical system (10) and the optical axis of the light focusing optical system (20). An angle (θS) between a sample (S) section by the excitation light beam and an axis (AF1) of a conveyance route (capillary C) is greater than 0° and smaller than 180°.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence

Abstract

A carbon-lithium sulfide composite in which the G/D area ratio in a Raman spectrum is 0.60 or less.

IPC Classes  ?

• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

The present disclosure provides a composition for treating or preventing fibrosis and/or inflammation in an organ or tissue in a subject. The present disclosure specifically provides a composition for treating or preventing fibrosis and/or inflammation in an organ or tissue in a subject, the composition containing macrophages derived from monocytes stimulated with IL-34. The composition can be produced by a method comprising: a step for preparing a sample comprising CD14-positive cells; an optional step for isolating the CD14-positive cells from the sample if required; and a step for bringing the sample or the isolated CD14-positive cells into contact with IL-34.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/20 - Interleukins
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/0786 - MonocytesMacrophages

Abstract

The present invention relates to new immunomodulatory thiourea and urea carbohydrate compounds of formula (I), pharmaceutical compositions comprising them and the use thereof, mainly as vaccine adjuvants, in the modulation of immune response in a subject, in the treatment and/or prophylaxis of infectious diseases and in the treatment of cancer.

IPC Classes  ?

• C07H 15/12 - Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of a saccharide radical
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed is a method for releasing carbon dioxide dissolved in a first alkaline solution, the method including: a step of preparing an anode electrode, a cathode electrode, and a cation exchange membrane that is disposed between the anode electrode and the cathode electrode, wherein the anode electrode includes a first catalyst and a first gas diffusion layer, and the cathode electrode includes a second catalyst, a second gas diffusion layer, and a water repellent layer; a step of filling the first alkaline solution, in which carbon dioxide is dissolved, between the anode electrode and the cation exchange membrane; a step of filling a second alkaline solution between the cation exchange membrane and the cathode electrode; a step of supplying a hydrogen-containing gas to the anode electrode at a flow rate of more than 0 cm/minute per electrode area of 1 cm2; and a step of supplying an oxygen-containing gas to the carbon dioxide at a flow rate of more than 0 cm/minute per electrode area of 1 cm2.

IPC Classes  ?

• B01D 61/44 - Ion-selective electrodialysis
• B01D 53/62 - Carbon oxides
• B01D 53/78 - Liquid phase processes with gas-liquid contact
• B01D 53/96 - Regeneration, reactivation or recycling of reactants
• B01D 61/46 - Apparatus therefor
• C01B 32/50 - Carbon dioxide

Abstract

The present invention provides a computer program, a method for generating a trained model, an information processing method, and an information processing device that can be expected to perform searching of time-series data related to substrate processing.　This computer program causes a computer to execute a process for generating a trained model that receives time-series data related to substrate processing as an input and outputs feature quantities of the time-series data, the computer program causing the computer to execute a process in which: training data in which time-series data related to substrate processing and a plurality of correct answer values related to a process performed on the basis of the feature quantities of the time-series data are associated with each other is acquired; time-series data of the acquired training data is inputted to the trained model, and feature quantities outputted by the trained model are acquired; a plurality of errors are calculated on the basis of the acquired feature quantities, the correct answer values for the training data, and a plurality of loss functions; the total error is calculated on the basis of the calculated plurality of errors; and the parameters of the trained model are updated on the basis of the calculated total error.

IPC Classes  ?

• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• G06F 16/906 - ClusteringClassification

Abstract

Provided is a strain sensor having high sensitivity to bending and tension. This strain sensor comprises: a flexible resin base material; conductive regions disposed on the resin base material and containing a laser-induced graphene; and a pair of electrodes electrically connected to the conductive regions. At least some of the conductive regions further contain a light-absorbing nanomaterial.

IPC Classes  ?

• G01B 7/16 - Measuring arrangements characterised by the use of electric or magnetic techniques for measuring the deformation in a solid, e.g. by resistance strain gauge

Abstract

This method for evaluating the amyloid β accumulation level in a brain comprises: a step for binding an exosome marker-specific binding substance (120) that specifically binds to an exosome marker (113) present on the surface of an exosome (110) and is labeled by a first nucleic acid fragment (121) to an exosome (110) obtained from a blood sample; a step for binding an amyloid β-specific binding substance (160) that specifically binds to amyloid β and is labeled by a second nucleic acid fragment (161) to the exosome (110) obtained from the blood sample; a step for using the first nucleic acid fragment (121) to detect the amount of the exosome (110) obtained from the blood sample; a step for using the second nucleic acid fragment (161) to detect the amount of the exosome (110) having amyloid β bound thereto; and a step for calculating the ratio of the amount of the exosome (110) having amyloid β bound thereto to the amount of the exosome (110) obtained from the blood sample.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/532 - Production of labelled immunochemicals

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• B01D 61/14 - UltrafiltrationMicrofiltration
• B01D 61/16 - Feed pretreatment
• B01D 61/22 - Controlling or regulating
• B01D 63/02 - Hollow fibre modules
• B01J 41/10 - Inorganic material
• B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 41/14 - Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 41/16 - Cellulose or woodDerivatives thereof
• B01J 41/18 - Carbon, coal or tar
• B01J 41/20 - Anion exchangers for chromatographic processes

Abstract

Disclosed herein are patches, methods, devices, and systems for delivering a non-aggregating peptide, such as alcadein and its fragments, into a subject. In some aspects, the patch includes a backing, a matrix comprising a non-aggregating peptides disposed within the matrix, and a release liner. In other aspects, the method includes opening at least one channel in the subject's skin, applying the patch described herein, thereby treating a disease or disorder associated with the brain, such as Alzheimer's disease.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention provides a method for predicting physical properties of a rubber material having high prediction accuracy. The present invention pertains to a method for predicting physical properties of a rubber material that is being continuously produced.

IPC Classes  ?

• G16C 60/00 - Computational materials science, i.e. ICT specially adapted for investigating the physical or chemical properties of materials or phenomena associated with their design, synthesis, processing, characterisation or utilisation
• G01N 3/00 - Investigating strength properties of solid materials by application of mechanical stress
• G06N 20/00 - Machine learning
• G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
• G06Q 50/04 - Manufacturing

IPC Classes  ?

• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

A method for producing a compound by using a flow micro reactor (100) includes: a step for introducing a first liquid containing a raw material compound having a fluorocarbon group into a first introduction tube (101) and introducing a second liquid containing an alkali metal cation and a radical anion of a second aromatic compound into a second introduction tube (103), to thereby obtain a first mixed liquid in a first micro mixer (107); a step for obtaining a first reaction product by causing the first mixed liquid to flow in a first tube reactor (109), and introducing an electrophile into a third introduction tube (105), to thereby obtain a second mixed liquid in a second micro mixer (111); and a step for causing the second mixed liquid to flow in a second tube reactor (113) to thereby obtain a second reaction product containing a compound which is formed by replacing, with atomic groups derived from the electrophile, one or more fluorine atoms in the fluorocarbon group in the raw material compound and which contains a fluorine atom.

IPC Classes  ?

• C07C 17/23 - Preparation of halogenated hydrocarbons by dehalogenation
• C07C 17/20 - Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms
• C07C 17/269 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of only halogenated hydrocarbons
• C07C 17/358 - Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or halogen atoms in the molecules by isomerisation
• C07C 22/08 - Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
• C07C 25/13 - Monocyclic aromatic halogenated hydrocarbons containing fluorine
• C07C 29/40 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy groups, e.g. O-metal by reaction with aldehydes or ketones with compounds containing carbon-to-metal bonds
• C07C 29/58 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by elimination of halogen, e.g. by hydrogenolysis, splitting-off
• C07C 33/46 - Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic part
• C07C 35/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
• C07C 41/24 - Preparation of ethers by reactions not forming ether-oxygen bonds by elimination of halogen, e.g. elimination of HCl
• C07C 43/225 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
• C07C 45/45 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by condensation
• C07C 47/24 - Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing halogen
• C07C 49/255 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
• C07C 49/813 - Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
• C07C 67/30 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
• C07C 69/65 - Halogen-containing esters of unsaturated acids
• C07C 209/74 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
• C07C 211/29 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
• C07C 211/30 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
• C07C 211/52 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
• C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
• C07C 217/84 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
• C07C 231/10 - Preparation of carboxylic acid amides from compounds not provided for in groups
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• C07C 233/12 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• C07C 255/32 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
• C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
• C07C 271/18 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
• C07C 273/18 - Preparation of urea or its derivatives, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
• C07C 275/30 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
• C07C 303/40 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
• C07C 311/16 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
• C07C 319/14 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
• C07C 321/28 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
• C07D 211/18 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
• C07D 211/52 - Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 279/28 - [b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
• C07F 7/12 - Organo silicon halides
• C07F 7/22 - Tin compounds
• C07F 9/42 - Halides thereof

Abstract

A method for producing 2,5-dimethylfuran according to one embodiment of the present invention includes a step for reacting a furan compound having a specific structure with hydrogen in a non-aqueous solvent in the presence of a hydrogenation catalyst. In this method for producing 2,5-dimethylfuran, the hydrogenation catalyst includes at least one type selected from among a first component group and at least one type selected from among a second component group. The first component group includes chromium, molybdenum, manganese, rhenium, ruthenium, rhodium, iridium, nickel, palladium, platinum, copper, zinc, and the like. The second component group includes aluminum oxide, silicon oxide, titanium oxide, zirconium oxide, carbon, and the like.

IPC Classes  ?

• C07D 307/36 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
• B01J 23/42 - Platinum
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• C07B 61/00 - Other general methods
• C07C 2/50 - Diels-Alder conversion
• C07C 15/08 - Xylenes
• C07C 51/16 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation
• C07C 63/26 - 1,4-Benzenedicarboxylic acid

Abstract

[Problem] To provide a lower-limb traction device comprising a boot that can firmly hold the range from around the calf to the toes of a patient. [Solution] A brace boot (10) adapted for a lower-limb traction device (1) is configured such that a calf holding unit (46) that holds the calf area of a patient and a sole holding unit (47) that holds the sole of the foot of the patient are connected to each other so as to rotate freely around a pair of support pins (92) and (92). Said configuration enables the brace boot (10) to firmly hold the range from around the calf to the toes of a patient, even for a patient suffering from, for example, ankle plantar flexion contracture in which the toes are flexed and contracted.

IPC Classes  ?

• A61G 13/12 - Rests specially adapted thereforArrangements of patient-supporting surfaces

Abstract

Task of the present disclosure is to provide a solanaceous plant and cells thereof and a method for producing the solanaceous plant where the plant has inhibitory properties against infection by a virus of genus Begomovirus causing tomato yellow leaf curl symptoms, propagation of the infected virus, and/or expression of infection symptoms, and the plant is resistant to the virus. The task is solved by providing a solanaceous plant having a mutation in at least one gene selected from a group consisting of DCL3 gene which is silencing associated dicer gene, 4CL06 gene which is 4-coumarate-CoA ligase gene, RLK2 gene which is receptor-like kinase gene, and genes homologous thereto. The mutation either inhibits the expression of the mutated gene or makes a protein encoded by the mutated gene to be non-functional for the virus, and the plant has virus resistance against the above-mentioned virus.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

Embodiments of the invention provide a solution to the problems associated with the lack of treatments for MARV and RAVV. The inventors have generated neutralizing mAbs to MARV that neutralize MARY infection. Certain mAbs are cross-reactive to MARV and RAVV.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/46 - Hybrid immunoglobulins
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided are an X-ray analysis information processing device, etc., capable of confirming characteristics, etc., of an object substance as an oxide based on an absorption amount of X-rays in a short time while eliminating human factors.　The present invention comprises: an absorption amount data input unit 1 that acquires an absorption amount of an X-ray object substance for spectroscopic analysis; an XANES region feature amount extraction unit 2B and an EXAFS region feature amount extraction unit 2C that, on the basis of the acquired absorption amount, extract, from a relationship between the irradiation energy of X-rays irradiated to the object substance and the absorption amount when the object substance is irradiated with the X-rays of the irradiation energy, a feature amount in the relationship; an oxide/valence determination unit 2D that detects a characteristic of the object substance on the basis of the extracted feature amount; and a result display control unit 2E that outputs the detected characteristic.

IPC Classes  ?

• G01N 23/085 - X-ray absorption fine structure [XAFS], e.g. extended XAFS [EXAFS]

Abstract

It is an object of the present invention to provide a novel technique of regulating mRNA splicing. Provided is an artificial RNA molecule comprising (a) a polynucleotide potentially having a secondary structure represented by the formula (I), wherein N1 to N25 each independently represents A, C, G, or U, or a polynucleotide in which 1 to 3 bases are substituted, deleted, or added among 7 bases on the 3′ side of the polynucleotide potentially having the secondary structure represented by the formula (I); and (b) a pre-mRNA targeting polynucleotide comprising a sequence complementary to a target sequence that is a portion of a pre-mRNA; wherein the (a) and the (b) are arranged from the 5′ side to the 3′ side in this order. It is an object of the present invention to provide a novel technique of regulating mRNA splicing. Provided is an artificial RNA molecule comprising (a) a polynucleotide potentially having a secondary structure represented by the formula (I), wherein N1 to N25 each independently represents A, C, G, or U, or a polynucleotide in which 1 to 3 bases are substituted, deleted, or added among 7 bases on the 3′ side of the polynucleotide potentially having the secondary structure represented by the formula (I); and (b) a pre-mRNA targeting polynucleotide comprising a sequence complementary to a target sequence that is a portion of a pre-mRNA; wherein the (a) and the (b) are arranged from the 5′ side to the 3′ side in this order.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

286464286428646464O particles is 1-20 nm.

IPC Classes  ?

• B22F 1/16 - Metallic particles coated with a non-metal
• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 1/14 - Treatment of metallic powder
• B22F 1/102 - Metallic powder coated with organic material
• B22F 9/20 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from solid metal compounds

Abstract

Provided is a wavelength control emitter having excellent heat resistance. A wavelength control emitter according to an embodiment of the present invention comprises a metal layer, a dielectric layer, a plurality of metal electrodes, and a coating layer. The dielectric layer is disposed on one side of the metal layer. The plurality of metal electrodes are arranged on the opposite side to the metal layer with respect to the dielectric layer. The plurality of metal electrodes are arranged at intervals from each other. The coating layer covers at least a part of the plurality of metal electrodes.

IPC Classes  ?

• H05B 3/10 - Heating elements characterised by the composition or nature of the materials or by the arrangement of the conductor
• H05B 3/20 - Heating elements having extended surface area substantially in a two-dimensional plane, e.g. plate-heater

Abstract

In order to provide a technology for selecting a sugar beet plant that has resistance to Virus Yellows disease, a determination method according to the present invention for determining the presence or absence of resistance to Virus Yellows disease in a sugar beet plant includes a determination step for identifying at least one locus pertaining to the resistance to Virus Yellows disease, either a locus between 11.0 Mbp and 30.0 Mbp on chromosome 4 or a locus between 8.0 Mbp and 38.0 Mbp on chromosome 7, to determine the presence or absence of the resistance.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• A01H 1/00 - Processes for modifying genotypes
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

22222C layer is subjected to cementation by an aluminum element.

IPC Classes  ?

• C23C 10/50 - Aluminising of ferrous surfaces
• C22C 21/00 - Alloys based on aluminium
• C22C 27/02 - Alloys based on vanadium, niobium or tantalum
• C22C 38/00 - Ferrous alloys, e.g. steel alloys

Abstract

An ammonia generation system (1) is provided with: an electrolysis cell (10) which generates ammonia from nitrogen and water, and is provided with a solid electrolyte (13) that contains a phosphoric acid compound which is a proton conductor; an ammonia separator (40) which is provided in a cathode outlet-side flow path (21) and separates ammonia from the cathode off gas; and a cathode-side circulation flow path (60) which is connected to the ammonia separator (40), and which returns, to the cathode (12), the residual gas that remains after the separation of ammonia by means of the ammonia separator (40) and contains nitrogen and hydrogen.

IPC Classes  ?

• C25B 1/27 - Ammonia
• C01C 1/04 - Preparation of ammonia by synthesis
• C01C 1/12 - Separation of ammonia from gases and vapours
• C25B 13/04 - DiaphragmsSpacing elements characterised by the material
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
• C25B 15/021 - Process control or regulation of heating or cooling

Abstract

A smoothing circuit (10) is provided with a positive electrode wire (11), a negative electrode wire (12), and a first capacitor part (C1) and a second capacitor part (C2) connected in parallel between the positive electrode wire and the negative electrode wire. The positive electrode wire has a first positive electrode connection portion (P1) connected to the first capacitor part, and a second positive electrode connection portion (P2) connected to the second capacitor part. The negative electrode wire has a first negative electrode connection portion (N1) connected to the second capacitor part, and a second negative electrode connection portion (N2) connected to the first capacitor part. The positive electrode wire and the negative electrode wire cross each other three-dimensionally. The inductance of the positive electrode wire is substantially equal to the equivalent series inductance of the first capacitor part, and the inductance of the negative electrode wire is substantially equal to the equivalent series inductance of the second capacitor part. The smoothing circuit comprises a snubber circuit (Cs) connected between the positive electrode wire and the negative electrode wire.

IPC Classes  ?

• H03H 7/09 - Filters comprising mutual inductance
• H01G 4/228 - Terminals
• H02M 7/48 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode

Abstract

Provided are: a non-invasive, simple, and compact interstitial pneumonia treatment device having a therapeutic effect on interstitial pneumonia; an interstitial pneumonia treatment system using the same; an interstitial pneumonia treatment method; a method for assisting in the detection of symptoms of interstitial pneumonia; and use of the device for treating interstitial pneumonia. The present invention pertains to: an interstitial pneumonia treatment device for reducing the symptoms of interstitial pneumonia of a subject suffering from interstitial pneumonia, the device comprising an auricular nerve stimulation means that is installed so as to be disposed at two or more different sites of the auricle of the subject and includes at least two electrodes configured so as to be capable of electrical stimulation at the two or more sites. Also provided are an interstitial pneumonia treatment system, an interstitial pneumonia treatment method, a method for assisting in the detection of symptoms of interstitial pneumonia, and use of the device for the treatment of interstitial pneumonia.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

2-x222-δ2-δ (0<δ≤0.5, preferably 0<δ≤0.3) in the reduced state. At least a part of the crystal structure of the active layer changes by causing a current to flow between the electrodes.

IPC Classes  ?

• H10N 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

Provided are: an alloy film having excellent environmental resistance even in an environment where corrosion and wear simultaneously occur at high temperatures; and an alloy from which the alloy film can be formed.　The Fe-based alloy is characterized by comprising, in terms of mass%, 10 ≤ Cr ≤ 40, 15 ≤ Ni ≤ 50, 0.03 ≤ C ≤ 0.9, 0.3 ≤ Si ≤ 2, and 1.5 ≤ B ≤ 3.5, with the remainder consisting of Fe and unavoidable impurities.

IPC Classes  ?

• C22C 38/00 - Ferrous alloys, e.g. steel alloys
• C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
• C22C 27/06 - Alloys based on chromium
• C23C 4/08 - Metallic material containing only metal elements
• C23C 4/18 - After-treatment

Abstract

To provide an information processing system and the like that learn in such a way as to effectively improve performance of an agent for a task requiring a plurality of steps. An information processing system according to the present disclosure includes: an agent configured to output a sequence of a plurality of actions including an action of outputting a command to an external tool in response to a user query; a feedback acquisition unit configured to acquire final feedback on the output sequence of the plurality of actions; and a parameter update unit configured to update a parameter of a model of the agent by using the feedback.

IPC Classes  ?

• G06F 9/448 - Execution paradigms, e.g. implementations of programming paradigms
• G06F 40/289 - Phrasal analysis, e.g. finite state techniques or chunking
• G06F 40/40 - Processing or translation of natural language

Abstract

This heat storage resistor comprises latent heat storage particles and a solid medium, and has an electric resistivity within the range of 1 × 10-7to 3 × 103Ω·cm, wherein: the latent heat storage particles each have a core particle and a coating part that covers at least part of the surface of the core particle; the core particle has, as a component thereof, a certain element or the like, and has a melting point of 100°C or higher; and the coating part has, as a component thereof, an element or the like that is different from the component of the core particle, does not cause chemical reaction with the core particle in an operation temperature range, and has an electric resistivity within the range of 1 × 10-7to 3 × 103Ω·cm.

IPC Classes  ?

• C09K 5/14 - Solid materials, e.g. powdery or granular
• F28D 20/02 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or using latent heat

Abstract

Provided are: a pharmaceutical composition, a blepharospasm treatment agent, and a hypersensitivity or dystonia treatment agent that have strong effects as treatments for blepharospasm and the like for which treatment has been heretofore difficult or there has been no effective treatment, and that cause little physical burden on patients; and a symptom model mouse having symptoms including blepharospasm, hypersensitivity, and dystonia. The pharmaceutical composition contains tramadol or a salt thereof as an active ingredient and is administered for treatment to a subject showing the symptoms of blepharospasm or hypersensitivity of the eye. The pharmaceutical composition contains 0.01-2.0% w/v of the tramadol or salt thereof. Also provided are a medicine, a blepharospasm treatment agent, and a hypersensitivity or dystonia treatment agent containing the foregoing. The symptom model mouse has symptoms including blepharospasm, hypersensitivity, and dystonia.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 27/02 - Ophthalmic agents

Abstract

A method for producing a hydrocarbon according to the present invention comprises: a step for making a metal and carbon dioxide react in water to produce a carbonate of the metal and hydrogen; and a step for making the hydrogen and carbon dioxide react in the water containing the carbonate of the metal to produce a hydrocarbon. The metal is at least one selected from the group consisting of iron, magnesium, zinc, and manganese.

IPC Classes  ?

• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
• C07B 61/00 - Other general methods
• C07C 9/04 - Methane

Abstract

6488O. With respect to scanning electron microscope images of the core copper particles, if the maximum length of each particle is defined as the long side, the arithmetic average value of the long sides is more than 1 μm, and with respect to the scanning electron microscope images, if the arithmetic average length of each particle having a ratio of the arithmetic average length of a portion that is orthogonal to the long side to the long side at 0.4 or less is defined as the thickness, the arithmetic average value of the ratio of the thickness to the long side is 0.25 or less.

IPC Classes  ?

• B22F 1/17 - Metallic particles coated with metal
• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 1/16 - Metallic particles coated with a non-metal
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

To provide a treatment plan evaluation system capable of supporting determination when a treatment plan is selected. A treatment plan evaluation system 1 that evaluates a treatment plan of a radiotherapy system RTS has a function of comparing a selected treatment plan with a record in which adoption of a past treatment plan has been determined, and provides a comparison result between the selected treatment plan and the record.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

A design device (100) includes: a beam generator (152) that repeatedly generates a plurality of new beams branching from a node closer to the leading end of an existing beam while changing at least one of a beam length, the number of branches, or a rotation angle about the axis of the existing beam on the basis of a preset rule so that a plurality of beams included in the network structure of a porous structure are generated in the design space acquired by an acquirer (151); and a node joiner (153) that selects a plurality of nodes that is not directly connected to each other through a beam, among the plurality of nodes generated by the beam generator (152), to join the selected nodes to generate a single node on the basis of a preset rule.

IPC Classes  ?

• G06F 30/18 - Network design, e.g. design based on topological or interconnect aspects of utility systems, piping, heating ventilation air conditioning [HVAC] or cabling

Abstract

This animal behavior recording device is provided with a processing unit which acquires animal behavior information, that is, information indicating the behavior of an animal, acquires animal position information, that is, information indicating the positions where the animal is present, estimates the behavior of the animal on the basis of the animal behavior information and the animal position information, and records the behavior in time series. Acceleration data acquired from an acceleration sensor disposed on the animal and/or angular velocity data acquired from an angular velocity sensor disposed on the animal can be used as the animal behavior information, and the processing unit is capable of estimating the behavior of the animal on the basis of one of the animal behavior information and the animal position information and correcting the estimated behavior by using the other information.

IPC Classes  ?

• A01K 11/00 - Marking of animals
• A01K 27/00 - Leads or collars, e.g. for dogs
• A01K 29/00 - Other apparatus for animal husbandry

Abstract

This field effect transistor has: a substrate having a (111) surface, the substrate comprising a group IV semiconductor doped with a first electroconductivity type; a core-shell nanowire including a core nanowire connected to the (111) surface of the substrate, the core nanowire comprising a group III-V compound semiconductor doped with a second electroconductivity type different from the first electroconductivity type, and a shell layer disposed so as to cover the core nanowire, the shell layer comprising a group III-V compound semiconductor doped with the first electroconductivity type; a first electrode electrically connected to the shell layer; a second electrode electrically connected to the substrate; and a gate electrode for inducing a field at the joining interface between the substrate and the core nanowire and at the shell layer.

IPC Classes  ?

• H10D 48/00 - Individual devices not covered by groups

Abstract

The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X  (I) The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X  (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-  (A) The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X  (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-  (A) —(CH2)d—N(R3)(R4)  (B)

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/1271 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
• A61K 9/51 - Nanocapsules
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

A carbon dioxide immobilization method includes: impregnating a cured cement body (10) with a carbon dioxide absorbing liquid containing a carbon dioxide absorbent (20) to obtain a cured cement body (1) for carbon dioxide immobilization, in which the carbon dioxide absorbent (20) is supported within the cured cement body (10); and bringing the cured cement body (1) for carbon dioxide immobilization into contact with air to immobilize carbon dioxide contained in the air in the cured cement body (1) for carbon dioxide immobilization.

IPC Classes  ?

• B01D 53/62 - Carbon oxides
• B01D 53/81 - Solid phase processes
• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/45 - Coating or impregnating
• C04B 41/46 - Coating or impregnating with organic materials
• C04B 41/62 - Coating or impregnating with organic materials
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

An optical device includes a substrate having a first region and a second region in a surface thereof, a first waveguide for inputting light, and at least one second waveguide for outputting light. The second region surrounds the first region. The first waveguide and the second waveguide are optically coupled to the first region. The substrate includes a first layer and a second layer sequentially stacked one on top of the other in the first region. The second layer has a plurality of holes. A depth of each of the holes is half of a thickness of the second layer or smaller. The substrate does not have the second layer and has the first layer in the second region.

IPC Classes  ?

• G02B 6/124 - Geodesic lenses or integrated gratings
• G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind

Abstract

[Problem] To improve workability. [Solution] This method comprises: a first step for subjecting fly ash to unburned carbon removal processing, thereby generating unburned carbon removal processed fly ash; a second step for subjecting the unburned carbon removal processed fly ash to mechanochemical processing and activating the surface of the unburned carbon removal processed fly ash; a third step for mixing a strong alkaline solution together with a silicon fine powder and preparing a silicon mixture in which a silicon component is eluted in the strong alkaline solution; and a fourth step for mixing the unburned carbon removal processed fly ash which has undergone surface activation together with the silicon mixture.

IPC Classes  ?

• C04B 28/26 - Silicates of the alkali metals
• B09B 3/25 - Agglomeration, binding or encapsulation of solid waste using mineral binders or matrix
• B09B 5/00 - Operations not covered by a single other subclass or by a single other group in this subclass
• C04B 18/08 - Flue dust

Abstract

A composite comprising: a skeleton having a porous structure and containing a crystalline SiO2 compound; and a fine particles including a metal oxide fine particles or a metal fine particle existing within the skeleton.

IPC Classes  ?

• B01J 29/06 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof
• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 35/23 - Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/45 - Nanoparticles
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 37/02 - Crystalline silica-polymorphs, e.g. silicalites

Abstract

A humanized antibody or a functional fragment thereof binding to a human-derived Eval protein, an antibody-drug conjugate comprising the humanized antibody or a functional fragment thereof, or a chimeric antigen receptor comprising an antibody or a functional fragment thereof binding to a human-derived Eval protein.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed are: a plasma solution containing a plasma coming from a first leukocyte removal filter through which human whole blood has been passed and a plasma coming from a second leukocyte removal filter through which the human whole blood has been passed, wherein the plasma coming from the second leukocyte removal filter is a plasma contained in a solution obtained by passing, through the second leukocyte removal filter, a solution containing the plasma coming from the first leukocyte removal filter; a platelet lysate; a method for producing the plasma solution; and a method for producing the platelet lysate.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system
• A61K 35/16 - Blood plasmaBlood serum
• A61K 35/19 - PlateletsMegacaryocytes
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

A latent heat storage particle that comprises a core particle and a coating part covering at least a part of the surface of the core particle, wherein: the core particle is composed of an element selected from the group consisting of Al, Mg, Si, Ti, Fe, Ni, Cu, Zn, Sn, Sb, Ga, In, Bi, Pb and Cd or an alloy or a compound mainly composed of the same and has a melting point of 100° C. or higher; the coating part is composed of one or more selected from the group consisting of an element different from the component of the core particle, an alloy and an inorganic compound containing the element and a mixture thereof, which does not undergo a chemical reaction with the core particle in the temperature range of the operating temperature; and at least a part of the coating part is in a particulate shape.

IPC Classes  ?

• C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
• B22F 1/16 - Metallic particles coated with a non-metal

Abstract

An object is to provide a mechanochemical-reaction additive that can be handled in the air, can be easily synthesized, can be used in a mechanochemical reaction to increase the activity of the mechanochemical reaction, and can be applied to wide-ranging substrates under mild conditions. A solving means provided is a mechanochemical-reaction additive including at least a ligand compound (Lx) or salt thereof, wherein the ligand compound (Lx) is one or more of a phosphorus-based compound, a bipyridine-based compound, and an N-heterocyclic carbene-based compound, and the ligand compound (Lx) intramolecularly has a polymer chain and the polymer chain is one or more of polyether, polyamide, polyester, and polyurethane.

IPC Classes  ?

• C08G 65/335 - Polymers modified by chemical after-treatment with organic compounds containing phosphorus
• C08G 65/333 - Polymers modified by chemical after-treatment with organic compounds containing nitrogen

Abstract

[Technical Problem] To provide a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy. [Solution to Problem]A pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition comprises a retinoic acid receptor (RAR) agonist is provided.

IPC Classes  ?

• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/203 - Retinoic acids
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

A catalyst structure for synthesis gas production is used to produce a synthesis gas that includes carbon monoxide and hydrogen. The structure includes a carrier with a porous structure that comprises a zeolite-type compound; first catalyst particles that contain at least one iron-group element selected from the group consisting of nickel, iron, and cobalt; and a second catalyst that contains at least one transition metal element with redox capacity. The carrier includes, inside thereof, mutually communicating passages; the first catalyst particles are present at least in the passages of the carrier; and the second catalyst is present at least in the interior or on an outer surface of the carrier.

IPC Classes  ?

• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 35/45 - Nanoparticles
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

The embolic agent according to the present invention includes as an active ingredient a copolymer of a cationic functional group-containing monomer and an aromatic group-containing monomer, the copolymer having at least a part thereof a structure represented by general formula (I) (in the formula, R11 and R12 are hydrogen atoms or alkyl groups having 1 to 20 carbon atoms which may have a substituent, and satisfy a relational formula: R11=R12; Y11 and Y12 are each independently a single bond or an alkylene group having 1 to 20 carbon atoms; Ar11 is an aromatic hydrocarbon group having 6 to 16 carbon atoms which may have a substituent; X11 is an ammonium group or an amino group; and n11 is an integer of 10 to 1,000.) The embolic agent according to the present invention includes as an active ingredient a copolymer of a cationic functional group-containing monomer and an aromatic group-containing monomer, the copolymer having at least a part thereof a structure represented by general formula (I) (in the formula, R11 and R12 are hydrogen atoms or alkyl groups having 1 to 20 carbon atoms which may have a substituent, and satisfy a relational formula: R11=R12; Y11 and Y12 are each independently a single bond or an alkylene group having 1 to 20 carbon atoms; Ar11 is an aromatic hydrocarbon group having 6 to 16 carbon atoms which may have a substituent; X11 is an ammonium group or an amino group; and n11 is an integer of 10 to 1,000.)

IPC Classes  ?

• A61L 24/06 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

This biomarker calculation apparatus holds radiation treatment plan information, immune cell number information in which the effect of irradiation with radiation on the number of immune cells in a patient is recorded, and definition information of a prediction model for predicting the time course of the number of immune cells. The prediction model includes internal parameters related to physical characteristics of the patient. The biomarker calculation apparatus determines an internal parameter of the prediction model using the immune cell count information, predicts the time course of the number of immune cells in the patient associated with the radiation therapy using the radiation treatment plan information and the prediction model, and calculates a biomarker correlated with a prognosis on the basis of the result of the prediction.

IPC Classes  ?

• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

A reaction-path search system calculates a reaction path in a structure formed of multiple atoms as a change in a structure represented by a positional relationship of the multiple atoms. The reaction-path search system including: a structural change calculation unit which calculates a change in the structure in which a result of a function FAFIR(Q) is at the minimum; a differential coefficient calculation unit which calculates at least one of a second differential coefficient b or a third differential coefficient a of E(Q) at the positions of the multiple atoms; and an equilibrium state change calculation unit which causes the structural change calculation unit to calculate the change in the structure in transition from the first equilibrium state to the second equilibrium state, prior to the other fragment pairs with lower priority than the fragment pair with higher priority based on the magnitude of a and b.

IPC Classes  ?

• G16C 20/40 - Searching chemical structures or physicochemical data
• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes

Abstract

A reservoir device receives input of time series sensor data measured in a predetermined process and outputs a reservoir feature value based on a result of processing using an input weight multiplier and a connection weight multiplier, in which the input weight multiplier weights the input sensor data, using a value determined by a periodic function as an input weight, and the connection weight multiplier performs weighted addition of data indicating states of nodes, using a value determined by a periodic function as a connection weight between two nodes among the nodes.

IPC Classes  ?

• G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]

Abstract

An antitumor agent according to the present disclosure contains, as an active ingredient, at least one component selected from the group consisting of ribozyme nucleic acids, antisense nucleic acids, RNAi-inducing nucleic acids, dominant negative variants, and aptamers, and vectors that express the same.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided is a method for efficiently producing heterologous T cell receptor or chimeric antigen receptor gene-introduced leukocytes.　The present invention relates to: a method for producing modified leukocytes, such as T cells to which heterologous a T-cell receptor or a chimeric antigen receptor gene has been introduced, by adding a ferroptosis inhibitor during the production step; and modified leukocytes produced by the method according to the present invention.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/13 - Immunoglobulins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention provides a neurite outgrowth promoter for promoting neurite growth on nerve cells of a postnatal mammalian individual for use in a condition in which an effective amount of a glial cell-derived neurotrophic factor (GDNF) is not present, the neurite outgrowth promoter containing at least one protein selected from the group consisting of: GDNF family receptor α1 (GFRα1): GFRα1 mutants having an amino acid sequence that has at least 90% sequence identity with the amino acid sequence of GFRα1, the GFRα1 mutants having neurite outgrowth activity; fusion proteins that have neurite outgrowth activity and that are obtained by fusing GFRα1 or a GFRα1 mutant with another peptide; and chemically modified proteins that have neurite outgrowth activity and that are obtained by chemically modifying one or a plurality of amino acid residues in GFRα1, a GFRα1 mutant, or a fusion protein. The present invention also provides a pharmaceutical composition for inducing nerve regeneration.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators

Abstract

The objective of the present invention is to alleviate a work load at the time of start-up in a prediction system equipped with a reservoir. This prediction system includes: a calibration-verified AI device in which a plurality of physical reservoirs for processing time-series signals are connected to each other; and a trained prediction device that reads outputs from the plurality of physical reservoirs included in the calibration-verified AI device while adding reading weights and outputs a predicted value. The calibration-verified AI device has the plurality of physical reservoirs verified to be calibrated so that the physical properties of the physical reservoirs are the same by adding M-series noise to the time-series signals. The trained prediction device has read weights duplicated from another trained prediction device that reads outputs from a plurality of other physical reservoirs having the same physical properties as the plurality of physical reservoirs while adding reading weights and outputs a predicted value, and that has read weights updated by training.

IPC Classes  ?

• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• G06N 3/065 - Analogue means